ArticlePloS one2012
Human endometrial stromal stem cells differentiate into megakaryocytes with the ability to produce functional platelets.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Identification and characterisation of maternal perivascular SUSD2Cell and tissue research · 2021Article
- Uterine Stem Cells and Benign Gynecological Disorders: Role in Pathobiology and Therapeutic Implications.Stem cell reviews and reports · 2021Review
- Platelet production using adipose-derived mesenchymal stem cells: Mechanistic studies and clinical application.Journal of thrombosis and haemostasis : JTH · 2021Review
- The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous.Frontiers in immunology · 2021Review
- Hemmule: A Novel Structure with the Properties of the Stem Cell Niche.International journal of molecular sciences · 2020Article
- Induction of differentiation of human stem cellsWorld journal of stem cells · 2019Review
- Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line.Blood · 2019Article
- Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications.Frontiers in bioengineering and biotechnology · 2019Article
- Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions.International journal of molecular sciences · 2018Review
- Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.Stem cell reviews and reports · 2017Review
- Platelet generation in vivo and in vitro.SpringerPlus · 2016Review
- The endometrium as a source of mesenchymal stem cells for regenerative medicine.Biology of reproduction · 2015Review
- Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease.Journal of cellular and molecular medicine · 2015Article
- Regenerative potential of endometrial stem cells: a mini review.World journal of plastic surgery · 2015Review
- Effects of endothelial progenitor cell-derived microvesicles on hypoxia/reoxygenation-induced endothelial dysfunction and apoptosis.Oxidative medicine and cellular longevity · 2013Article
- Endometrial stem/progenitor cells: the first 10 years.Human reproduction updateReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Human endometrium is a high dynamic tissue that contains endometrial stromal stem cells (hESSCs). The hESSCs have been differentiated into a number of cell lineages. However, differentiation of hESSCs into megakaryocytes (MKs) has not yet been investigated. The aim of this study was to investigate the feasibility of MK generation from hESSCs and subsequent production of functional platelets (PLTs). In our study, hESSCs were cultured from endometrial stromal cells as confirmed by positive stromal cell specific markers (CD90 and CD29) and negative hematopoietic stem cell markers (CD45 and CD34) expression. Then, hESSCs were differentiated in a medium supplemented with thrombopoietin (TPO) for 18 days. The MK differentiation was analyzed by flow cytometry and confocal microscopy. The differentiation medium was collected for PLT production analysis by flow cytometry, transmission electron microscopy and functional measurements. Our results show: 1) MKs were successfully generated from hESSCs as identified by expression of specific markers (CD41a: 1 ± 0.09% and 39 ± 3.0%; CD42b: 1.2 ± 0.06% and 28 ± 2.0%, control vs. differentiation) accompanied with reduction of pluripotent transcription factors (Oct4 and Sox2) expression; 2) The level of PLTs in the differentiation medium was 16 ± 1 number/µl as determined by size (2-4 µm) and CD41a expression (CD41a: 1 ± 0.4% and 90±2.0%, control vs. differentiation); 3) Generated PLTs were functional as evidenced by the up-regulation of CD62p expression and fibrinogen binding following thrombin stimulation; 4) Released PLTs showed similar ultra-structure characteristics (alpha granules, vacuoles and dense tubular system) as PLTs from peripheral blood determined by electron microscopic analysis. Data demonstrate the feasibility of generating MKs from hESSCs, and that the generated MKs release functional PLTs. Therefore, hESSCs could be a potential new stem cell source for in vitro MK/PLT production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.